New research has shown that screening or testing for past Epstein-Barr virus infections can help find people at a higher risk ...

Background: Nasopharyngeal carcinoma (NPC) is a type of malignant tumors commonly found in Southeast Asia and China, with insidious onset and clinical symptoms. N6-methyladenosine (m6A) modification ...

Background: Nasopharyngeal carcinoma (NPC) is a highly invasive malignant tumor. Recurrence and distant metastasis represent the primary causes of treatment failure. This study aimed to identify ...

Dr Reddy's Laboratories on Thursday said it has launched Toripalimab, a drug for the treatment of recurrent or metastatic ...

Dr. Reddy’s announced the launch of Toripalimab in India on Thursday, for patients diagnosed with nasopharyngeal carcinoma (NPC), a rare form of head and neck cancer. Toripalimab, a New Biological ...

Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India. Toripalimab, a PD-1 inhibitor, provides a new treatment option for this rare ...

In this special report, JOHNSON IDOWU writes on how the abandoned Abesan Primary Healthcare Centre building in Lagos has ...

New Delhi, Nov 28 (PTI) Dr Reddy's Laboratories on Thursday said it has launched Toripalimab, a drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma in India. Nasopharyngeal ...

“The launch of Toripalimab is a significant milestone for patients diagnosed with nasopharyngeal carcinoma (NPC) in India. NPC is a rare form of head and neck cancer. However, the prognosis of ...

The stock climbed after the company announced the launch of Toripalimab in India. Toripalimab (Loqtorzi) is a drug used to treat certain types of nasopharyngeal carcinoma (NPC), a type of head and ...

Oncology has been a top focus therapy area for the company which has been able to launch Toripalimab in India in the same year as its launch in the US, he added. "We will continue to work hard to ...

Objective The role of cigarette smoking as an independent risk factor for patients with nasopharyngeal carcinoma (NPC) is controversial. We attempted to provide evidence of a reliable association ...